Poliovirus strains derived from the oral poliovirus vaccine (Sabin) can be differentiated from wildtype poliovirus by tests based on either immunological or genetic properties of the strains. The characterization of a recently identified poliovirus type 1 isolate with exceptional properties is described. Initial phenotypic analysis of the virus by use of polyclonal absorbed antisera suggested a wild-type character. However, the different genomic analyses all confirmed the Sabin-derived character of the virus. All 17 plaques isolated from the strain shared these properties, thus excluding the possibility of a mixture of a wild-type and a Sabin-derived strain. To elucidate the properties of this virus further, the nucleotide sequences of the P1 region and most of the 5h noncoding region were established. Although the nucleotide identity with Sabin 1 was more than 99n4 %, mutations were observed in regions encoding three major antigenic sites ; the deduced amino acid substitutions confirmed the aberrant results of micro-neutralization assays with sitespecific monoclonal antibodies. The most striking feature was the existence of a hexanucleotide deletion in the VP1 gene, which gave rise to a two amino acid deletion in the BC loop. In spite of these antigenic changes, the strain was readily serotyped as poliovirus type 1 under standard conditions. Likewise, replication of the virus under cell culture conditions was not affected by these mutations or by the deletion. Standard polio vaccination protects against this aberrant virus, and its epidemiological significance remains open.
Introduction
Polioviruses, the causative agents of poliomyelitis, represent three serotypes in the genus Enterovirus (family Picornaviridae). The virions consist of a single-stranded, messenger-sense RNA and 60 copies of each of the four capsid proteins VP1 to VP4. Like other RNA viruses, polioviruses exist as mixtures of microvariants, called quasispecies (Domingo et al., 1996) . This is caused by the error-prone, virusencoded RNA polymerase, which lacks proof-reading activity, resulting in a rapid accumulation of mutations upon replication Author for correspondence : Mick Mulders.
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(reviewed in Holland et al., 1992) . Another well-known characteristic of poliovirus that contributes to genetic variability is its ability to recombine with other serotypes (intertypic recombinants : Cammack et al., 1988 ; Johnson & Semler, 1988 ; King, 1988 ; Lipskaya et al., 1991 ; Furione et al., 1993) or with another genome of the same serotype (intratypic recombinants : Zheng et al., 1993 ; Georgescu et al., 1994 ; Friedrich et al., 1996) . During replication in humans, and upon transmission between hosts, some of the mutations generated are enriched. The process depends on various selecting factors, or occurs just by chance. This has resulted in numerous genetic lineages within each serotype of poliovirus that co-circulate worldwide .
The deadline of the global polio eradication initiative coordinated by the World Health Organization (WHO) is approaching rapidly. Eradication may not be accomplished in the year 2000 itself, but it is imminent. The success of this programme could not be achieved without the highly effective, live, attenuated oral poliovaccine (OPV), as formulated by Albert Sabin (Sabin & Boulger, 1973) . The advantages of this vaccine are numerous, e.g. it confers lifelong humoral and mucosal immunity, it is cheap to produce and easy to administer and it is fairly stable (Melnick, 1996) . There are, however, a few disadvantages, the most prominent being the frequent reversion to neurovirulence upon replication in humans (Macadam et al., 1989 ; Dunn et al., 1990 ; Georgescu et al., 1994) and the capacity to cause vaccine-associated paralytic poliomyelitis (VAPP), which occurs in approximately one case per 750 000 first doses of OPV (CDC, 1997) .
It is evident that towards the end of the eradication campaign, the role of the virus diagnostic laboratories is increasing, as all poliovirus isolations from paralytic cases require virological follow-up to elucidate the source of the agent. That is, whether the paralysis is due to a wild-type infection or to VAPP, or to infection with a non-polio enterovirus causing polio-like symptoms (Melnick, 1984 ; Hayward et al., 1989) . In a large majority of cases, this differentiation does not pose any difficulties. Here, we describe one exception, a type 1 poliovirus strain, derived from the Sabin 1 strain, but displaying striking genetic and phenotypic differences from the parent virus.
Methods
Case report. The patient was a 9-year-old boy from a western district of Turkey. He was diagnosed with measles on April 18, 1997. Ten days later, he fell ill with suspected encephalitis, as he suffered from asymmetric loss of sense in the extremities and face, and he was not able to talk or eat properly. He also suffered from temporary paralysis of the face and upper and lower extremities, which commenced on April 29, 1997. He had, however, no residual paralysis, and has not been classified as a case of poliomyelitis. The patient had probably received normal polio vaccinations as an infant and had not received any vaccine immediately prior to the onset of the current disease. A faecal specimen for virological analysis was obtained on May 7, 1997.
Virus isolation and initial characterization. At the Refik Saydam Institute of Hygiene in Ankara, Turkey, the faecal specimen (16\97\182) was processed according to standard protocols for virus isolation and characterization (WHO, 1992) . Poliovirus type 1 was isolated. This isolate, together with the original stool suspension, was sent to the National Institute of Public Health and the Environment (RIVM) in Bilthoven, The Netherlands, to confirm these findings and to characterize this isolate further . Intratypic differentiation (ITD) of the isolate, a test aimed at establishing whether the strain was wild-type or Sabin vaccine-derived, was carried out using an ELISA with cross-absorbed polyclonal antisera (PoAb-EIA ; van Wezel & Hazendonk, 1979) and a hybridization assay with Sabin-specific RNA probes (De et al., 1995) .
RT-PCR. This technique was used for three separate assays : (i) to demonstrate the presence of Sabin vaccine-derived virus, with an assay targeting the 5h end of the VP1 gene (Sabin-PCR ; Yang et al., 1991) , (ii) PCR restriction fragment length polymorphism assay (PCR-RFLP ; Balanant et al., 1991) and (iii) amplicon sequencing (Mulders et al., 1995 b) . The primers used in this study are described in Table 1 . Viral RNA was isolated from fully lysed cell culture supernatants by using the RNeasy kit (Qiagen). To simplify the different amplification assays, identical reaction conditions were chosen for all PCR assays. Reverse transcription was carried out in a 20 µl reaction volume for 30 min at 42 mC, and the reaction contained 25 mM Tris-HCl (pH 8n3 at 25 mC), 5 mM MgCl # , 50 mM KCl, 2 mM DTT, 1 mM dNTPs, 25 pmol downstream or reverse primer, 5 U avian myeloblastosis virus reverse transcriptase (Finnzymes Oy), 5 U RNasin (Promega) and 2 µl heat-denatured RNA. Upon completion, the reaction was heated for 5 min at 95 mC to inactivate the enzyme and the reaction mixture was immediately thereafter chilled on ice. The reaction was adjusted by adding 8 µl 10i PCR buffer [0n1 M Tris-HCl (pH 8n8 at 25 mC), 0n5 M KCl, 1 % Triton X-100], 1n5 µl 50 mM MgCl # , 25 pmol upstream primer, 1 U recombinant Thermus brockianus DNA polymerase (DyNAzyme II, Finnzymes Oy) and water to a final volume of 100 µl. PCR cycling conditions were according to the original publications (Balanant et al., 1991 ; Yang et al., 1991 ; Mulders et al., 1995 b) . After visualizing the PCR products on ethidium bromide-stained, 2 % agarose gels, PCR mixtures were purified by using the Qiaex PCR purification kit (Qiagen) for subsequent sequence analysis. Purified products were used for non-radioactive cycle sequencing by using fluorescein-labelled ddNTPs according to the manufacturer's instructions (Perkin-Elmer).
Antigenic characterization. A micro-neutralization assay, using poliovirus monoclonal antibodies (MAbs) specific for antigenic sites 1 to 4 of poliovirus serotype 1 (Osterhaus et al., 1983 ; Ferguson et al., 1986 ), was performed to study possible antigenic differences of the isolate to the parental Sabin strain (LS-c, 2ab) and the neurovirulent Mahoney strain, from which the Sabin type 1 strain was derived (Table 4 ). The assay was performed as described below (J. H. J. Reimerink, H. G. A. M. van der Avoort, A. M. van Loon and M. P. G. Koopmans, unpublished results). Briefly, serial 2-fold MAb dilution series were made, in duplicate, in Eagle's MEM supplemented with 10 % foetal calf serum and 0n02 M HEPES, in a 96-well microtitre plate. One hundred TCID &! of the poliovirus strain was added to each well and incubated for 2 h at 37 mC. Subsequently, 50 µl of a cell suspension containing 3i10& HEp-2C cells was added to each of the wells. The plates were then sealed, and incubated at 37 mC until full cytopathic effect was observed in the virus controls. Each neutralization assay included Sabin type 1 virus and prototype wild strain Mahoney as controls.
Assays for virus growth. Virus growth was estimated by studying one-step growth curves in monolayer cultures of African green monkey kidney (GMK) cells and recombinant murine cells expressing the human poliovirus receptor (L20B : Mendelsohn et al., 1986 ; Pipkin et al., 1993) . Parallel wells in 24-well plates were inoculated with undiluted virus stocks. After adsorption for 1 h at 35 mC or at an elevated temperature (39n5 mC), the unadsorbed inoculum was removed, maintenance medium was added and plates were incubated at 35 mC or 39n5 mC. At 8 and 24 h post-infection (p.i.), wells were harvested and total virus concentration was determined by the end-point dilution method in microwell plates.
To study plaque morphology, monolayers of L20B and GMK cells in a 24-well plate were inoculated with 50 µl serial 10-fold virus dilutions prepared in maintenance medium. After 1 h at 37 mC, a semi-solid carboxymethyl cellulose overlay was added. After incubation at 37 mC, plates were stained with crystal violet at 1, 2 and 3 days p.i.
Plaque purification was carried out at 24 h p.i. from plates resulting from a similar experiment, by picking plaques of 10-30 infected cells (approx. 5 µl), under a microscope with low-power magnification, with a pipette tip. After mixing the picked plaques with maintenance medium, samples were stored at k20 mC until inoculation on cell culture.
A naturally occurring poliovirus deletion mutant A naturally occurring poliovirus deletion mutant Table 1 . Primers used in this study
Numbering of nucleotide positions is according to Nomoto et al. (1982) . 
Results

Intratypic differentiation (ITD) assays
The two WHO-recommended ITD assays aimed at discriminating wild-type from Sabin-derived virus strains (van der Avoort et al., 1995) gave conflicting results. By PoAb-EIA, the poliovirus type 1 was labelled as wild-type (Table 2) , whereas by Sabin-specific cRNA-probe hybridization, a positive signal was obtained, indicating the presence of a Sabin-derived strain (data not shown). Table 2 . Intratypic differentiation of strain 97-30515 by using cross-absorbed polyclonal antisera ITD was carried out according to van Wezel & Hazendonk (1979) . Sabin vaccine and wild Mahoney serotype 1 reference strains are controls. The numbers are crude absorbances. For a wild-type or nonSabin-like result, the specific absorbance obtained with the non-Sabinlike antiserum must have a value of at least 0n700 and be at least three times that obtained with the Sabin-like antiserum, and vice versa for the Sabin-like result.
Absorbance Strain
Sabin-like* Non-Sabin-like † Total ‡ Background Sabin 1  2n50  0n24  2n86  0n19  97-30515  0n43  2n85  3n82  0n22  Mahoney  0n33  2n55  3n38  0n20 * Poliovirus type 1\Sabin-specific absorbed antiserum used. † Poliovirus type 1\Mahoney-specific absorbed antiserum used. ‡ Unabsorbed poliovirus type 1-specific antiserum used. 
Additional molecular characterization
We performed additional assays to elucidate the phenotypic and genetic characteristics of this isolate further. In the Sabin-PCR, a positive signal was obtained (data not shown). RFLP analysis of the VP3\VP1 junction region amplicon gave a similar restriction pattern to that of Sabin 1. However, there was a slight shift in mobility of one of the fragments to a lower molecular mass, suggesting that the entire amplicon was smaller than the Sabin fragment (Fig. 1) . This gel mobility shift was observed most prominently in the DdeI restriction analysis. The overall RFLP pattern differed significantly from the Mahoney pattern.
Heterogeneity of the isolate
To exclude the possibility that isolate 97-30515 was a mixture of both Sabin-derived and wild-type viruses, a plaquepurification assay was performed. In total, 17 plaques were A naturally occurring poliovirus deletion mutant A naturally occurring poliovirus deletion mutant Nomoto et al. (1982) . The Sabin sequence is of isolate LS-c, 2ab (GenBank accession number V01150) and the Mahoney sequence is GenBank accession number J02281. p11, Plaque 11 ; p14, plaque 14 ; cons, conserved genomic region ; hyvar, hypervariable genomic region. -, Sequences compared were identical at this position ; ∆, deletion. 
picked. After cell culture amplification, all individual plaques were analysed by PoAb-EIA, Sabin-PCR and RFLP ; the fragment used for RFLP analysis was also sequenced from 10 plaques. All 17 plaques gave identical results in the PoAb-EIA, as all were characterized as wild-type. The viral RNA derived from all 17 plaques was characterized as being Sabin-derived in the Sabin-PCR. When the same RNA was subjected to RFLP analysis, all plaques gave identical bands as the original isolate, except for plaque 11, which gave a different restriction pattern with HaeIII. This was confirmed by subsequent sequence analysis of the amplicon of this plaque, where a mutation was found in the HaeIII recognition sequence (GG\CC to AG\CC), resulting in the loss of this site. Plaque 14 also differed by one nucleotide from the original isolate, 97-30515, but this had no Table 4 . Results of micro-neutralization assay using site-specific MAbs
All MAbs are poliovirus type 1 specific. Sabin 1 is a positive control for Sabin-like (SL) characteristics ; Mahoney is a positive control for wild-type (wt) characteristics. Antigenic site nomenclature according to Minor (1990) . MAbs 237 and 423 have been used previously by Minor et al. (1986) and MAbs 14D2E9 and 3D8 have been used previously by Osterhaus et al. (1983) . effect on the restriction pattern. This mutation, however, did change the deduced amino acid sequence at position 26 in VP1 (Ala #' Thr #' ). The VP3\VP1 sequences of the remaining eight plaques were identical to the consensus sequence of strain 97-30515.
Final evidence of Sabin vaccine origin
The partial genomic nucleotide sequence of strain 97-30515 was established by amplicon sequencing of overlapping fragments spanning the entire P1 structural region, including most of the 5h non-coding region (5h NCR) and a small part of the 2A pro gene (Fig. 2) .
The sequence (3390 nt) thus obtained revealed several interesting genetic features. The overall sequence identity with the Sabin strain was greater than 99n4 %, while that with the Mahoney wild prototype strain was slightly lower (98n7 %). Table 3 shows the observed differences between strain 97-30515 and Sabin 1 and Mahoney. Position 480, located in the 5h NCR, which is associated with neurovirulence (Minor, 1992) , had not reverted, but had maintained its attenuated character (G att vs A vir ). Nucleotide position 476, however, had mutated (U A). In the hypervariable part of the 5h NCR, two mutations were observed (positions 655 and 691).
In the coding region, mutations resulting in different amino acid codons were found at several positions. Although the internal VP4 had remained unchanged, mutations were found in all other capsid genes. In VP2, a mutation in the neutralization antigenic site (N-Ag) IIb was found (Asp Asn at position 165), while in VP3 a mutation was found in N-Ag IIIb at amino acid position 60 (Lys Val), where a double mutation in the amino acid codon was found (AAA GTA). In VP1, the gene for the major capsid protein, several coding mutations were found : Fig. 2 b) ; Asn "%" Ser "%" (position 142 is part of N-Ag I) and most importantly a hexanucleotide in-frame deletion between positions 2783 and 2788 that resulted in a two amino acid deletion at positions 102 and 103 in VP1, which are located in or close to N-Ag I.
Antigenic analyses
The results of a micro-neutralization assay using MAbs specific for different antigenic sites of poliovirus type 1 are given in 
GMK cells
MAbs 956 (site 1 specific), 423, 3D8, 1D4E8 or 1D7 (all site 3 specific). The remaining two antigenic sites (2 and 4) were only analysed with MAbs that neutralize wild-type and Sabinderived strains with similar efficiency (237 and 14D2E9, site 2 specific ; 234, site 4 specific). Strain 97-30515 was also neutralized by these MAbs. Finally, MAbs (4-9D8E10 and 5-18D8) that could differentiate intratypically, but for which the site specificity is not known, were included in this assay. They favoured the wild-type character of the virus. Serum neutralization of strain 97-30515 was carried out with sera from 20 healthy individuals vaccinated either with the inactivated poliovaccine (IPV) or with OPV (Table 5) . Neutralization titres obtained with strain 97-30515 were similar to those for the prototype vaccine strain Sabin 1 and Mahoney.
Growth pattern in cell culture
To investigate the virus growth characteristics, we examined replication of this virus in two different cell lines at two different temperatures (Table 6 ). In GMK cells, the mutant strain appeared to be heat stable, as growth at the elevated temperature (39n5 mC) was comparable to that of the wild-type Mahoney, whereas the attenuated Sabin strain was temperature sensitive as expected (3 log difference in titre). Growth on L20B cells was different, as the virus now appeared to have the growth characteristics of Sabin 1.
The overall plaque morphology of strain 97-30515 on GMK cells was comparable to the Sabin strain, giving small plaques when grown at 37 mC. Mahoney, as expected, showed larger plaques. In L20B cells, there was no difference in plaque size between the three strains.
Discussion
Towards the end of the global initiative to eradicate poliomyelitis and its causative agent, poliovirus, increasing effort is being put into finding the last remaining wild virus. In this process, ITD is being performed on every poliovirus isolate. Usually, results obtained with antigenic and genetic differentiation methods are in full agreement, but occasionally, intermediate reaction patterns are seen in antigenic characterization of a strain. In this report, we present detailed antigenic and genetic characterization of such a virus (97-30515), which is Sabin vaccine derived, but displays extreme deviant behaviour. According to immunological analysis using intratype-specific, cross-absorbed polyclonal antisera, the strain appeared definitely wild-type. Further analysis using sitespecific MAbs to at least three different epitopes and analysis of growth characteristics at elevated temperature in a monkey kidney cell line supported this view.
The genetic analyses, however, all contradicted the phenotypic analyses. cRNA-probe hybridization, Sabin-specific PCR, RFLP-PCR and amplicon sequencing revealed the Sabinderived character of this virus. Putative mixing of wild-type and vaccine-derived virus strains was excluded by plaque purification. The nucleotide sequence of the entire P1 region and part of the 5h NCR and 2A clearly revealed the Sabinderived, and not Mahoney-derived, origin of this strain. The Sabin 1 strain is itself a descendant of the Mahoney strain, displaying differences at 58 nucleotide positions across its entire genome. Upon comparison with the Sabin 1 sequence, a total of 19 positions showed mutations (total 3390 nt sequenced). When comparing the sequence obtained from 97-30515 with the Mahoney sequence, 44 positions were different. Only two of the observed mutations, as compared with the Sabin sequence, were identical with the corresponding locations in the Mahoney sequence, making the likelihood of more direct Mahoney origin quite small. It is striking that all but one (position 1621 in VP2) of the mutations observed in the P1 capsid region were coding mutations (two point mutations in VP2, a double mutation in VP3, three point mutations and a hexanucleotide deletion in VP1). The genetic changes are most likely the result of several replication cycles within one individual, or of repeated passages between persons. Of the six coding changes, five had occurred in, or in close proximity to, one of the antigenic sites of the virus. This explains the drastic change in the antigenic character of the virus. It is remarkable, however, that the overall serotype identity was not disturbed by these antigenic changes, as polyclonal typing antisera readily neutralized strain 97-30515. The high proportion of coding mutations as compared with the parental Sabin strain suggests that immune selection has been a major factor in the emergence of strain 97-30515. During the type 3 poliovirus epidemic in Finland in 1984-1985, striking antigenic variation was found among the epidemic strains (Huovilainen et al., 1988) . The low level of immunity in the M. N. Mulders and others M. N. Mulders and others Finnish population prior to the epidemic (Lapinleimu, 1984) may have provided a suitable environment for the generation of the antigenic changes observed. Similarly, the high proportion of coding mutations in poliovirus type 1 strain 97-30515 might reflect replication of the virus in vivo in individuals with a low level of pre-existing immunity.
In the 5h NCR, the putative neurovirulence marker at position 480 has remained as G, as in the parental Sabin strain, and hence the attenuated character of the virus might not be affected. However, we have not tested the neurovirulence of this strain. The effect of the mutation at position 476, which is located in the same stem-loop domain V (Skinner et al., 1989) , most likely has a stabilizing effect on the stem-loop structure in this domain. It is known that markers located in other parts of the genome, not only in the P1 capsid region but also in the 3D pol region (position 6203), are important for the attenuation of neurovirulence in poliovirus type 1 (Minor, 1992 ; Bouchard et al., 1995) . The positions in the P1 region that might be involved in the attenuation of poliovirus type 1, at positions 935 of VP4, 2438 of VP3 and 2795 and 2879 of VP1 (Bouchard et al., 1995) , all remained identical to the Sabin sequence.
The most prominent feature of this virus can be found in VP1, the major capsid protein. We do not know how the deletion mutant has emerged, but a possible mechanism for the hexanucleotide deletion in N-Ag I is a genomic rearrangement due to imprecise homologous recombination, where a hexanucleotide jump has occurred during strand-switching of the RNA polymerase (for recent review see Agol, 1997) .
To our knowledge, this is the first report of a poliovirus field isolate with a deletion in the coding region. Previously, a neutralization-escape mutant had been isolated that had the entire BC loop deleted, between positions 94 and 102, comprising N-Ag I (Couderc et al., 1991) . This deletion mutant, however, had been isolated during laboratory experiments on engineered viruses, where neutralization-escape mutants of chimeric type 1 viruses were found in which the BC loop was replaced with that of a type 2 virus. Just like strain 97-30515, this virus remained stable upon passage, and the nine amino acid deletion did not have any significant effect on virus viability. The deletion did result in the loss of mouse neurovirulence and rendered the virus temperature sensitive. In our case, infectivity and growth characteristics, as estimated in cell culture of recombinant murine cells expressing the human poliovirus receptor (L20B cells), were intermediate between Sabin 1 and Mahoney. The deletion in N-Ag I may not have a major effect on virus-cell interaction or on receptor binding. The observed differences in growth could be a result of the other mutations. The plaque morphology of 97-30515 on GMK cells of monkey origin was comparable to Sabin plaques. One other publication reported the isolation of six Sabin-derived polioviruses from VAPP cases with various degrees of mutation (Georgescu et al., 1997) . However, in that study, only one virus showed a similar extent of mutation to strain 97-30515. This strain had also reverted to neurovirulence. We have partially characterized another antigenically aberrant Sabin 1-derived field strain, isolated in 1996 in Hong Kong. According to the reactivity of N-Ags with sitespecific MAbs, this strain was also highly mutated. The partial VP1 sequence, encompassing N-Ag I, showed five codon changes between positions 95 and 106, but no deletion (data not shown). These viruses are all examples of modified Sabin 1 viruses circulating freely in nature. That field isolations of such aberrant viruses have not been observed more frequently might be explained by the fact that, although many wild-type isolates are sequenced partially to establish the source of the virus (reviewed in Kew et al., 1995) , the region analysed is relatively short (150 nt).
Despite the extensive degree of mutation in three of the four antigenic sites, the neutralization data obtained using human antisera indicate that protection upon vaccination with either vaccine is sufficient, which is reassuring. The emergence of such aberrant Sabin vaccine-derived polioviruses might pose a problem towards the end of the global polio eradication initiative, where all field isolations require virological followup to determine the source of the virus. If such a virus were analysed by only one method, based on phenotypic characterization, the resulting outcome would be incorrect, namely wild-type. As eradication of wild-type poliovirus requires certification, such an aberrant virus might subsequently have a negative influence on the progress of eradication. Therefore, it is clear that improved virological examination is needed, including one or more molecular characterization methods.
